Effect of Compound Danshen Dripping Pills on cardiac function after acute anterior ST-segment elevation myocardial infarction: A randomized trial

The current study aimed to evaluate the efficacy and safety of Compound Danshen Dripping Pills (CDDP) in improving cardiac function among patients with acute anterior ST-segment elevation myocardial infarction (AAMI). Between February 2021 and February 2023, 247 eligible patients with AAMI after primary percutaneous coronary intervention (pPCI) were enrolled and randomly assigned (1∶1) to receive CDDP (n = 126) or placebo (n = 121), with a follow-up of 48 weeks. Compared with the placebo group, the CDDP group demonstrated a significant increase in left ventricular ejection fraction (LVEF) values after 24 weeks of the treatment (least squares mean: 3.31; 95% confidence interval CI: 1.72–4.90; P < 0.001) and at the 48-week follow-up (least squares mean: 4.35; 95% CI: 2.76–5.94; P < 0.001). Significant reductions of N-terminal pro-B-type natriuretic peptide levels were observed in both groups at the 24- and 48-week visits without difference between the two groups (P > 0.1 for all), and 6.35% and 5.79% of patients in the CDDP and placebo groups experienced major adverse cardiovascular and cerebrovascular events, respectively (P = 0.822). Therefore, no serious adverse events were attributed to CDDP. These findings sugget that CDDP was well tolerated and improved LVEF of patients with AAMI in 24 and 48 weeks.